Successful Treatment of Intralesional Triamcilonon Acetonide Injection in Keloid Patients
DOI:
https://doi.org/10.3889/oamjms.2019.093Keywords:
Keloid, Triamcinolone acetonideAbstract
AIM: Evaluation the effect of intralesional corticosteroid injection on keloid, at the National Hospital of Dermatology and Venereology from 1/2009 to 12/2009.
METHODS: A group of 65 patients with keloid were randomly assigned into three groups. In the studied group, 33 patients were intralesionally injected 7.5 mg/1 cm2 of TCA. In the control group, TAC 32 patients were intralesionally injected 15 mg/1 cm2 of TCA. The result was evaluated basing on the criteria of Henderson (1998) and El-Tonsy (1996).
RESULTS: In comparison between 2 groups, good to excellent improvement in the studied group was statistically higher than the control group (90.7% versus 68.7%; p < 0.05). After each injection, the thickness of the scar was reduced 1.24 ± 0.53 mm in the studied group and 0.81 ± 0.39 mm in the control group. The disappearance of pain and itching after treatment were 86.6% and 95.5% in the studied group and 78.1% and 80% in the control group (p > 0.05). Ulceration, acne and troublesome with menstrual cycles were sometimes were noted more frequently in the control group than in the studied group.
CONCLUSION: Intralesional triamcinolone acetonide injection had a good result, and 7.5 mg/1 cm2 scar is the best dose for treatment of keloid.
Downloads
Metrics
Plum Analytics Artifact Widget Block
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Nghi Dinh Huu, Sau Nguyen Huu, Xuan Le Thi, Thuong Nguyen Van, Phuong Pham Thi Minh, Trang Trinh Minh, Tam Hoang Van, Van Tran Cam, My Le Huyen, Khang Tran Hau, Marco Gandolfi, Francesca Satolli, Claudio Feliciani, Micheal Tirant, Aleksandra Vojvodic, Torello Lotti

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)
